Recurrent venous thrombosis under rivaroxaban and carbamazepine for symptomatic epilepsy by Stöllberger, Claudia & Finsterer, Josef
Case report
Recurrent venous thrombosis under rivaroxaban
and carbamazepine for symptomatic epilepsy
Claudia Stöllberger *, Josef Finsterer
Krankenanstalt Rudolfstiftung, Wien, Austria
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 1 ( 2 0 1 7 ) 1 9 4 – 1 9 6
a r t i c l e i n f o
Article history:
Received 7 September 2016
Accepted 19 January 2017







a b s t r a c t
Background: The direct oral anticoagulant (DOAC) rivaroxaban, an oral Factor Xa inhibitor, is
increasingly used as an alternative to vitamin-K-antagonists (VKAs). Absorption and elimi-
nation of DOACs are dependent on the permeability glycoprotein (P-gp) efﬂux transporter
protein system, and DOACs are substrates of the hepatic cytochrome P 450 3A4 (CYP3A4)
enzymes. Therefore, drug-interactions may occur when DOACs are administered with drugs
affecting the activity of P-gp or CYP3A4 systems. Several antiepileptic drugs like carbamaz-
epine are known to affect P-gp and CYP3A4-activity.
Case report: A 55-year-old male was admitted because of pain and swelling of his right leg
spontaneously since 2 days. He was under a therapy with 20 mg rivaroxaban since 4 months
because of an unprovoked venous thrombosis of his right leg. He had a history of poliomy-
elitis at age 6 months, structural epilepsy due to poly-microgyria with complex partial
seizures with secondary generalization since age 6 years, why he was treated with carba-
mazepine (900 mg/d). He reported to be highly adherent to his anticoagulant and antiepi-
leptic medication. Anti-Xa activity was <20 ng/ml according to a rivaroxaban calibrated anti-
factor Xa assay. Therapy with rivaroxaban was stopped, and low-molecular-weight heparin,
followed by phenprocoumon, was started.
Conclusion: The combination of DOACs with carbamazepine, an inducer of P-gp and CYP3A4-
activity, should be avoided since the anticoagulant effect is decreased. There is an urgent
need to increase our knowledge and physicians' awareness about the potential of drug–drug
interactions of DOACs.
© 2017 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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The direct oral anticoagulant (DOAC) rivaroxaban, an oral
Factor Xa inhibitor, is increasingly used as an alternative to
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assumed to overcome some of the limitations of VKAs due
to fewer food- and drug-interactions and a more predictable
anticoagulant effect, thus allowing ﬁxed dosing without the
need for laboratory monitoring.
Intestinal absorption and renal elimination of DOACs are
dependent on the intestinal and renal permeability glycopro-udolfstiftung, Juchgasse 25, 1030 Wien, Austria.
(C. Stöllberger).
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Table 1 – Results of blood tests at admission.
Parameter (reference) Day 1
BUN, mg/dl (9–20) 10
Creatinine, mg/dl (<1.1) 0.94
Creatinine clearance (Cockcroft–Gault), ml/min (>90) 141
Glomerular ﬁltration rate (modiﬁcation of diet in
renal disease), ml/min/1.73 m2 (>90)
83
Haemoglobin, g/dl (14–17) 16.0
Thrombocytes/nl (150–450) 257
INR 1.24
Prothrombin time, % (70–130) 71.0
Activated partial thromboplastin time, s (25–36) 37.7
Thrombin time, s (10–17) 14.1
ALAT, U/l (10–50) 31
Bilirubin, mg/dl (<1.2) 0.22
Gamma-GT, U/l (0–60) 84
Carbamazepine level, mmol/l (therapeutic
range 33.8–50.8)
41.7
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several DOACs like rivaroxaban are substrates of the hepatic
cytochrome P 450 3A4 (CYP3A4) enzymes [4]. Thus, drug-
interactions may occur when DOACs are administered
concomitantly with drugs affecting the activity of P-gp or
CYP3A4 systems. Coadministration with P-gp- or CYP3A4-
inducing agents may lead to a decrease in the serum levels and
thus, decrease anticoagulant activity of DOACs, whereas
coadministration with P-gp- or CYP3A4-inhibiting agents
may lead to an increase in the serum levels and thus, increase
anticoagulant activity of DOACs. Several antiepileptic drugs
are known to affect P-gp and CYP3A4-activity, however the
clinical relevance of this drug–drug interaction with DOACs is
largely unknown [5]. We recently observed a patient with
recurrent venous thrombosis under a therapy with rivarox-
aban and carbamazepine.
2. Case description
A 55-year-old Caucasian male was admitted because of
increasing pain and swelling of his right leg starting
spontaneously 2 days before admission. He was under a
therapy with 20 mg rivaroxaban since 4 months because of an
unprovoked venous thrombosis of his right leg. At that time
neither abdominal sonography nor gastroscopy or colonosco-
py had shown any signs of malignancy, and blood tests for
carcinoembryonal antigen, carbohydrate antigen, alpha feto-
protein and prostate speciﬁc antigen were within normal
range. Screening for thrombophilia including measurements
of protein C, protein S, APC resistance and antiphospholipid
antibodies had been negative, He had a history of poliomyelitis
at age 6 months with residual spastic hemiparesis on the right
side, structural epilepsy due to central and occipital poly-
microgyria with complex partial seizures with secondary
generalization since age 6 years, excision of a melanoma of the
left upper extremity at age 53, recurrent lumbar spinal disc
herniations since 10 years and a left-sided hemicastration
because of a benign ﬁbrosing testicular tumour at age 48 years.
As an antiepileptic medication he took carbamazepine
(900 mg/d). He was seizure-free during the last 11 years. He
reported to be highly adherent to the prescription of his
anticoagulant and antiepileptic medication. During several
neurologic follow-up visits within the last 11 years, his serum
carbamezepine-levels were within the therapeutic range at
any time when they were measured. He reported not take any
other medication or diet supplements, except carbamazepine
and rivaroxaban. Regarding risk factors for thrombosis, he
reported that an aunt had suffered from venous thrombosis. At
clinical examination at admission he presented with a blood
pressure of 130/80 mm Hg, pulse was 75/min and regular. His
height was 180 cm, weight 113 kg and body mass index 34.9.
Except for swelling of the right lower limb the remaining
clinical examination was normal and no varices were
detected. Duplex sonography showed a thrombosis of the
right popliteal and femoral vein. Results of blood tests are
listed in Table 1. The serum-carbamazepine level was within
the therapeutic range. Anti-Xa activity was <20 ng/ml accord-
ing to a rivaroxaban calibrated anti-factor Xa chromogenic
assay 23 h after intake of the last 20 mg rivaroxaban [6].Therapy with rivaroxaban was stopped, and low-molecular-
weight heparin, followed by phenprocoumon, was started. The
swelling and pain in his leg decreased and he was discharged
with compression stockings after 5 days.
3. Discussion
Most likely, recurrence of venous thrombosis of the presented
patient was the result of insufﬁcient anticoagulation due to
drug–drug interaction between rivaroxaban and carbamaze-
pine, which is a known inducer of P-gp and CYP 3A4-activity
[7,8]. This is supported by the missing serum anti-Xa activity in
our patient, who was adherent and took the medication
according to the prescription.
Whereas the drug–drug interaction between VKAs and
carbamazepine are known for more than 20 years, and the
mechanism is identiﬁed as CYP3A4 induction by carbamaze-
pine, little is known about the inﬂuence of carbamazepine on
DOAC-induced anticoagulation [9,10]. In the literature, a 53-
year-old man is reported, who had just undergone partial knee
arthroplasty and suffered from pulmonary embolism, diag-
nosed by computed tomography, one day after thrombosis
prophylaxis was switched from dalteparin 5000 IU QD to
rivaroxaban 10 mg QD. The patient also used carbamazepine
600 mg BID for epilepsy [11]. The authors hypothesized that
carbamazepine, a CYP3A4 inducer, probably led to an
increased clearance of rivaroxaban resulting in pulmonary
embolism. No further reports about drug–drug interactions
between carbamazepine and the DOACs apixaban, edoxaban
or dabigatran are found in the literature. Since all DOACs,
however, are substrates of the P-gp, and apixaban as well as
edoxaban are also CYP3A4-substrates it can be expected that
their anticoagulant effect might also be attenuated by
carbamazepine [5].
According to the summary of product characteristics of
rivaroxaban, as published by the European Medicines Agency
(EMA), the concomitant use of rivaroxaban with strong CYP3A4
inducers (e.g. phenytoin, carbamazepine, phenobarbital or St.
John's Wort) may lead to reduced rivaroxaban plasma
concentrations. Therefore, according to EMA, concomitant
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unless the patient is closely observed for signs and symptoms
of thrombosis [12].
Whereas interactions between VKAs and any other drug are
easily detected because of deviations of the INR, in patients on
DOAC, no laboratory test is easily available to detect the drug–
drug interaction. Also in our patient, there was only a minimal
prolongation of the activated partial thromboplastin time
which might indicate an effect of rivaroxaban [13].
From our ﬁndings we conclude that the combination of
DOACs with carbamazepine should be avoided since their
anticoagulant effect may be decreased by a drug–drug
interaction. There is an urgent need to increase our knowledge
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